130.08
前日終値:
$128.12
開ける:
$126.485
24時間の取引高:
756.08K
Relative Volume:
0.67
時価総額:
$13.08B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
27.87
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
-0.88%
1か月 パフォーマンス:
+1.33%
6か月 パフォーマンス:
-5.79%
1年 パフォーマンス:
+21.25%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
130.08 | 12.89B | 2.86B | 478.60M | 748.70M | 4.6676 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.34 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
114.03 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.295 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
570.67 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine, Soleno HSR waiting period expired April 27 - MLex
Neurocrine Biosciences-Soleno Therapeutics HSR waiting period expired April 27 - MLex
Neurocrine (NASDAQ: SLNO) to acquire Soleno for $53.00 per share after HSR clearance - Stock Titan
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unlocking a 45% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - msn.com
Wall Street analysts think Neurocrine (NBIX) could surge 38.79%: Read this before placing a bet - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results - simplywall.st
Neurocrine to buy Soleno for treatment for rare disease that causes relentless hunger - MSN
Munich Reinsurance Co Stock Corp in Munich Buys 10,168 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT - MSN
CRENESSITY Phase 3 Data on Lower Steroid Doses Could Be A Game Changer For Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Raised to Strong-Buy at Wall Street Zen - MarketBeat
NBIX News | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN
Ruffer LLP Invests $2.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Deutetrabenazine Market to Witness Massive Growth by 2033 |Teva - openPR.com
Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com India
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine reports sustained glucocorticoid reductions in CAH study - Investing.com
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider
Rare adrenal disorder drug helped 7 in 10 adults cut steroid doses - Stock Titan
NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00 - MarketBeat
Belpointe Asset Management LLC Acquires Shares of 9,485 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals
3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Yahoo Finance
NBIX Stock Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN
Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unveiling a 39.92% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
KBC Group NV Has $4.60 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cwm LLC Purchases 11,306 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus
Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus
How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):